Loading...
XASX
UCM
Market cap2mUSD
Jul 09, Last price  
0.02AUD
1D
6.25%
1Q
-19.05%
Jan 2017
-93.06%
IPO
-99.24%
Name

Uscom Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
1.14
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.91%
Rev. gr., 5y
0.46%
Revenues
4m
+39.89%
480,1071,119,622871,2631,051,7131,630,371836,913837,995794,135578,7531,056,5022,039,4262,936,5043,498,9592,861,7083,641,9583,479,7583,858,0812,509,6832,664,1663,726,845
Net income
-2m
L-19.92%
-2,545,918-3,374,210-3,196,824-2,174,484-1,099,889-1,757,677-2,685,913-1,824,547-1,371,683-1,520,500-1,215,654-1,915,029-1,800,849-1,960,923-1,389,398-1,331,335-924,243-1,972,313-2,590,888-2,074,749
CFO
-1m
L-18.30%
-2,588,370-3,187,788-3,266,151-1,671,190-1,016,237-1,497,877-2,194,324-1,656,182-971,576-1,235,738-992,796-1,290,796-952,042-1,696,625-1,219,480-283,22554,978-967,515-1,424,022-1,163,393
Earnings
Sep 04, 2025

Profile

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company also provides the SpiroSonic AIR, a digital multipath ultrasonic spirometer with a viral disinfection system for the elimination of COVID and tuberculosis; and respiratory devices. It serves hospitals and other medical care locations through a network of distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.
URL
https://www.uscom.com.au/
IPO date
Dec 10, 2003
Employees
35
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
3,727
39.89%
2,664
6.16%
Cost of revenue
6,131
8,128
Unusual Expense (Income)
NOPBT
(2,404)
(5,463)
NOPBT Margin
Operating Taxes
47
(395)
Tax Rate
NOPAT
(2,452)
(5,069)
Net income
(2,075)
-19.92%
(2,591)
31.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,914
(665)
BB yield
-72.31%
Debt
Debt current
300
263
Long-term debt
1,679
1,658
Deferred revenue
Other long-term liabilities
105
92
Net debt
(625)
(342)
Cash flow
Cash from operating activities
(1,163)
(1,424)
CAPEX
(8)
(152)
Cash from investing activities
(58)
(152)
Cash from financing activities
1,573
(953)
FCF
(2,116)
(3,968)
Balance
Cash
2,520
2,179
Long term investments
83
83
Excess cash
2,417
2,129
Stockholders' equity
3,061
3,044
Invested Capital
1,739
2,099
ROIC
ROCE
EV
Common stock shares outstanding
176,462
173,341
Price
0.02
 
Market cap
2,647
 
EV
2,022
EBITDA
(2,018)
(5,081)
EV/EBITDA
Interest
132
103
Interest/NOPBT